Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
Conditions
Keywords
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness, Hair Loss Baldness
Brief summary
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
Interventions
A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
Sponsors
Aderans Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female volunteers 18 to 65 years old, inclusive * Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle. * Have no clinically significant disease or abnormal laboratory results taken at the screening visit. * Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, finasteride or dutasteride during the course of this study (other than minoxidil as required in this study).
Exclusion criteria
* Known sensitivity to DMEM/F-12 or any component of the study material. * Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate. * Subjects who have used any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening (with the exception of minoxidil). * A history of drug or alcohol abuse within 1 year of study enrollment. * Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator. * Any clinically significant abnormal laboratory parameters. * A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II. * Dermatologic condition in donation or treatment area. * Prior surgery in the treatment and/or study areas. * Insufficient hair or scarring in the donor area that might impact cell growth. * Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk. * Hypersensitivity to minoxidil or the ingredients in the topical solution or foam formulations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in hair number | 51 weeks post-injection |
| Change from baseline in hair width | 51 weeks post-injection |
| Time course of any treatment benefit | 51 weeks post-injection |
Secondary
| Measure | Time frame |
|---|---|
| Effect of minoxidil | Week 12, 18, 24, 33 and 51 post-injection |
Countries
United States
Outcome results
None listed